Performance of Machine Learning Models to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections
Sunday, April 24, 2022
2:00 PM – 2:15 PM US MT
Location: Convention Center: Four Seasons Ballroom 4
CE: Enduring CME: 0.25
Publication Number: 2455.5
Nathan Kuppermann, University of California, Davis, School of Medicine, Sacramento, CA, United States; Silvia Bressan, University of Padova, Padova, Veneto, Italy; Caroline Wang, Baylor College of Medicine, Houston, TX, United States; Octavio Ramilo, Nationwide Children's Hospital, Columbus, OH, United States; Prashant Mahajan, University of Michigan Medical School, Ann Arbor, MI, United States; Hooman H. Rashidi, UC Davis, Cleveland, OH, United States
Participants should be aware of the following financial/non-financial relationships:
Silvia Bressan, MD,PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Nathan Kuppermann, MD, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Caroline Wang, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Octavio Ramilo, MD: ● Adagio (Ended In the Past 24 Months) (Products/Services: Advisory Committee). ● Lilly (Ended In the Past 24 Months) (Products/Services: Advisory Committee). ● Merck (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Advisory Committee). ● Pfizer (Currently Ongoing) (Products/Services: Consultant, Advisory Committee). ● Sanofi (Currently Ongoing) (Products/Services: Advisory Committee).
Prashant Mahajan, MD MPH MBA: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Hooman H. Rashidi, MD: ● MILO ML LLC (Currently Ongoing) (Products/Services: Board Member or Executive Role, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).
